NasdaqGS - Delayed Quote • USD
Crinetics Pharmaceuticals, Inc. (CRNX)
At close: May 14 at 4:00 PM EDT
After hours: May 14 at 7:30 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 13 | 14 | 13 |
| Avg. Estimate | -0.86 | -0.87 | -3.52 | -3.79 |
| Low Estimate | -1.06 | -1.11 | -4.25 | -5.06 |
| High Estimate | -0.69 | -0.77 | -3.19 | -2.97 |
| Year Ago EPS | -0.94 | -1.01 | -3.69 | -3.52 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 11 | 12 |
| Avg. Estimate | 510k | 260k | 2.09M | 17.79M |
| Low Estimate | -- | -- | 600k | 3M |
| High Estimate | 2.5M | 1M | 5.6M | 61M |
| Year Ago Sales | 988k | 120k | 4.01M | 2.09M |
| Sales Growth (year/est) | -48.40% | 116.70% | -47.90% | 751.20% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.86 | -0.86 | -0.86 | -0.81 |
| EPS Actual | -0.94 | -1.01 | -0.9 | -0.93 |
| Difference | -0.08 | -0.15 | -0.04 | -0.12 |
| Surprise % | -9.30% | -17.40% | -4.70% | -14.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.86 | -0.87 | -3.52 | -3.79 |
| 7 Days Ago | -0.8 | -0.84 | -3.29 | -3.54 |
| 30 Days Ago | -0.8 | -0.84 | -3.29 | -3.54 |
| 60 Days Ago | -0.8 | -0.83 | -3.29 | -3.49 |
| 90 Days Ago | -0.76 | -0.92 | -3.41 | -3.84 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 2 | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 6 | 7 | 6 | 6 |
Growth Estimates
| CURRENCY IN USD | CRNX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 8.50% | -- | -- | 7.30% |
| Next Qtr. | 13.90% | -- | -- | 10.90% |
| Current Year | 4.60% | -- | -- | 4.60% |
| Next Year | -7.70% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -- | -- | -- | 10.89% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/14/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/10/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 5/10/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 5/7/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 3/28/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/20/2024 |
Related Tickers
MRUS Merus N.V.
44.77
-2.36%
JANX Janux Therapeutics, Inc.
47.91
-4.16%
CYTK Cytokinetics, Incorporated
59.36
+2.54%
DNLI Denali Therapeutics Inc.
19.75
+2.33%
SNDX Syndax Pharmaceuticals, Inc.
21.66
+3.29%
APGE Apogee Therapeutics, Inc.
54.00
+2.41%
RYTM Rhythm Pharmaceuticals, Inc.
40.38
+0.45%
ARVN Arvinas, Inc.
31.36
-0.67%
KRYS Krystal Biotech, Inc.
159.47
+3.00%
EWTX Edgewise Therapeutics, Inc.
17.44
-0.23%